Comparative Pharmacology
Head-to-head clinical analysis: JANUMET versus SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUMET versus SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE.
JANUMET vs SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), increasing endogenous incretin hormones (GLP-1, GIP) which enhance insulin secretion and decrease glucagon levels in a glucose-dependent manner. Metformin activates AMP-activated protein kinase (AMPK), decreasing hepatic glucose production and improving insulin sensitivity.
Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.
Initial dose based on current metformin dose: for patients not on metformin, start with sitagliptin 50 mg/metformin 500 mg PO BID; for metformin monotherapy, switch to sitagliptin 50 mg/metformin 500 mg or 1000 mg PO BID; for patients on sitagliptin, start with sitagliptin 50 mg/metformin 500 mg or 1000 mg PO BID. Maximum daily dose: sitagliptin 100 mg, metformin 2000 mg.
None Documented
None Documented
Sitagliptin: 12.4 hours (terminal). Clinical context: supports once-daily dosing, but half-life increases in renal impairment. Metformin: 6.2 hours (terminal). Shorter half-life requires multiple daily dosing; prolonged in renal impairment.
Sitagliptin: terminal t1/2 12.4 hours, allows once-daily dosing. Metformin: terminal t1/2 6.2 hours, accumulates with renal impairment.
Sitagliptin: 87% renal (unchanged), 13% fecal (metabolites). Metformin: 90-100% renal (unchanged), <5% fecal.
Sitagliptin: 87% renal excretion as unchanged drug, 13% fecal (biliary). Metformin: 90% renal excretion as unchanged drug, 10% fecal.
Category C
Category A/B
DPP-4 Inhibitor/Biguanide Combination
DPP-4 Inhibitor